SURFACE LOGIX ANNOUNCES THE APPOINTMENT OF LELAND WEBSTER AS VICE PRESIDENT OF CORPORATE DEVELOPMENT
BOSTON, Mass. (August 21, 2007)
- Surface Logix is pleased to announce the appointment
of Leland Webster, Ph.D., M.B.A., as Vice President,
Corporate Development. As a member of the management
team, Dr. Webster will primarily be responsible for
leading the development and execution of Surface Logix’s
business strategy and corporate partnering activities.
Dr. Webster will also have responsibility for corporate
communications.
"I am extremely pleased to welcome
Leland to the Surface Logix management team. I look
forward to working with him as we near Phase IIa proof
of concept for our two lead compounds, SLx-2101 and
SLx-4090, the achievement of which will result in
significant value creation in the context of partnering
and funding discussions," said Jim Mahoney, CEO of
Surface Logix. "Leland’s scientific background combined
with his business training and 11 years of biotechnology
industry experience in business development brings a
valuable mix of skills and experience to our company as
we continue to both advance our clinical programs and
exploit our core Pharmacomer™ Technology.”
Prior to joining Surface Logix, Dr.
Webster led business development at ImmunoGen, Inc.,
most recently as an Executive Director. Previously, he
held positions of increasing responsibility in business
development at Vertex Pharmaceuticals. Before that, Dr.
Webster was a Senior Analyst at MPM Capital L.P.
Dr. Webster holds a B.A. in
Biological Sciences from Northwestern University and a
Ph.D. in Biochemistry from the University of
Pennsylvania, and served as a Damon Runyon-Walter
Winchell postdoctoral fellow in the Department of
Biological Chemistry and Molecular Pharmacology at the
Harvard Medical School. Dr. Webster also earned an
M.B.A. from the MIT Sloan School of Management.
About Surface Logix
Inc.
Surface Logix Inc. uses
its expertise in biophysical chemistry to create
and develop novel small molecule drugs (NCEs) with
superior intrinsic drug-like properties that are clearly
differentiated from competitive products. The company
is advancing multiple internal programs focused
primarily on cardiovascular, metabolic, inflammatory and
fibrotic diseases. For more information, please visit
http://www.surfacelogix.com.
Contact:
Leland Webster, Ph.D., M.B.A.
Surface Logix Inc.
Vice President, Corporate Development
617.746.8520
Media:
Kari Watson
MacDougall Biomedical Communications Inc.
kwatson@macbiocom.com
508.647.0209
|
